doctor examines patient data on their tablet

TAVR, SAVR both linked to low reintervention rates after five years

While most TAVR-related reinterventions occurred in the first year after treatment, most SAVR-related reinterventions occurred in years two through five. The team's full analysis is available in JACC: Cardiovascular Interventions.

First-in-human trial shows potential of guiding CABG with cardiac CT and AI—no ICA required

An independent heart team blinded to ICA results was able to deliver helpful guidance for CABG procedures for 99.1% of patients using just CCTA and FFRCT alone. This approach is safe and feasible, researchers wrote, and the next step is to gather additional data. 

ACC attendees get training on how to place a temporary pacemaker in the hands-on simulation lab at ACC.24. Photo by Dave Fornell

ACC in-person attendance surpasses pre-COVID numbers for first time 

"We were thrilled with the meeting and the attendance," ACC President Cathie Biga, RN, told Cardiovascular Business.

ACC.24: New data suggest early PCI limits risks of vulnerable plaques—cardiologists are skeptical

The PREVENT study, presented at ACC.24, examined more than 1,600 patients with high-risk plaques treated with either preventive PCI or medical therapy alone. Outcomes were much better for the PCI group after two years, but the findings may lead to more questions than answers. 

Newsweek ranked the 50 best heart hospitals in the world

ACC.24: TAVR linked to lower 1-year mortality, stroke rates than SAVR in low-risk patients

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

Foluso Fakorede, MD, interventional cardiologist, Cardiovascular Solutions of Central Mississippi, explains how he moved to rural Mississippi, the epicenter of the PAD and CLI epidemic, to open a practice to take action and reverse the glaring health disparities and that are leading to more than 400 leg amputations per day in the U.S.

Cardiologist moves to Mississippi to fight back against PAD and limit amputations

Interventional cardiologist Foluso Fakorede, MD, opened a practice in rural Mississippi, the epicenter of the PAD and CLI epidemic, to try and reverse the glaring health disparities in that region.

ACC.24 sign American College of Cardiology

ACC.24: Impella CP boosts survival for patients with STEMI-related cardiogenic shock

“This is the first time in a very long time that we have a positive study for managing cardiogenic shock,” one cardiologist said. 

ACC.24 late-breaking clinical trials

ACC.24: Self-expanding Evolut valves offer superior performance for TAVR patients with small annuli

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women.